Targeted treatment with pazopanib in metastatic soft tissue sarcoma: Nearly complete response in two cases
- Authors:
- Published online on: November 13, 2014 https://doi.org/10.3892/mco.2014.456
- Pages: 400-402
Metrics:
Total
Views: 0 (Spandidos Publications: | PMC Statistics:
)
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics:
)
Abstract
Soft tissue sarcomas (STS) are a group of rare mesenchymal cancers that include approximately 50 histological types and account for 1% of all adult cancers. The standard curative treatment option for localized disease is surgical resection and, if a surgically removed tumor exhibits high‑risk characteristics, adjuvant chemotherapy and radiotherapy may be administered. Sarcoma presenting at an advanced stage has a dismal prognosis and survival has not markedly improved over the last 20 years. The standard first-line treatment for advanced sts, other than gastrointestinal stromal tumors, is cytotoxic chemotherapy. Therapies targeting pro‑angiogenic factors have been a focus of drug development for STS over the last few years. Pazopanib, a multitargeted tyrosine kinase inhibitor, is a novel treatment option for patients with metastatic sts in the second‑line setting. This is a presentation of 2 case reports of patients with metastatic sts who responded well to treatment with pazopanib.
